Tryton begins trial of side branch stent
This article was originally published in Clinica
Executive Summary
Tryton Medical, of Durham, North Carolina, has initiated a registry study of its Tryton side branch stent. Called E-Tryton 150, the study is one of four registries in Europe evaluating the Tryton device in real-world clinical settings. It will enrol 150 patients with a primary endpoint of overall rate of major adverse cardiac events (MACE) – defined as cardiac death, myocardial infarction and target lesion revascularisation (main and/or side branch) – at six months following the procedure. The study will also assess the technical and procedural success of the stent. Designed to treat bifurcated atherosclerotic lesions, the cobalt chromium Tryton side branch stent is used in conjunction with a conventional drug-eluting stent. It was CE marked in February 2008.
You may also be interested in...
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.